Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan 21;384(3):216-228.
doi: 10.1056/NEJMoa2028220. Epub 2020 Nov 13.

Polypill with or without Aspirin in Persons without Cardiovascular Disease

Salim Yusuf  1 , Philip Joseph  1 , Antonio Dans  1 , Peggy Gao  1 , Koon Teo  1 , Denis Xavier  1 , Patricio López-Jaramillo  1 , Khalid Yusoff  1 , Anwar Santoso  1 , Habib Gamra  1 , Shamim Talukder  1 , Courtney Christou  1 , Preeti Girish  1 , Karen Yeates  1 , Freeda Xavier  1 , Gilles Dagenais  1 , Catalina Rocha  1 , Tara McCready  1 , Jessica Tyrwhitt  1 , Jackie Bosch  1 , Prem Pais  1 ; International Polycap Study 3 Investigators
Collaborators, Affiliations
Randomized Controlled Trial

Polypill with or without Aspirin in Persons without Cardiovascular Disease

Salim Yusuf et al. N Engl J Med. .

Abstract

Background: A polypill comprising statins, multiple blood-pressure-lowering drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease.

Methods: Using a 2-by-2-by-2 factorial design, we randomly assigned participants without cardiovascular disease who had an elevated INTERHEART Risk Score to receive a polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily, aspirin (75 mg) or placebo daily, and vitamin D or placebo monthly. We report here the outcomes for the polypill alone as compared with matching placebo, for aspirin alone as compared with matching placebo, and for the polypill plus aspirin as compared with double placebo. For the polypill-alone and polypill-plus-aspirin comparisons, the primary outcome was death from cardiovascular causes, myocardial infarction, stroke, resuscitated cardiac arrest, heart failure, or revascularization. For the aspirin comparison, the primary outcome was death from cardiovascular causes, myocardial infarction, or stroke. Safety was also assessed.

Results: A total of 5713 participants underwent randomization, and the mean follow-up was 4.6 years. The low-density lipoprotein cholesterol level was lower by approximately 19 mg per deciliter and systolic blood pressure was lower by approximately 5.8 mm Hg with the polypill and with combination therapy than with placebo. The primary outcome for the polypill comparison occurred in 126 participants (4.4%) in the polypill group and in 157 (5.5%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.63 to 1.00). The primary outcome for the aspirin comparison occurred in 116 participants (4.1%) in the aspirin group and in 134 (4.7%) in the placebo group (hazard ratio, 0.86; 95% CI, 0.67 to 1.10). The primary outcome for the polypill-plus-aspirin comparison occurred in 59 participants (4.1%) in the combined-treatment group and in 83 (5.8%) in the double-placebo group (hazard ratio, 0.69; 95% CI, 0.50 to 0.97). The incidence of hypotension or dizziness was higher in groups that received the polypill than in their respective placebo groups.

Conclusions: Combined treatment with a polypill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participants without cardiovascular disease who were at intermediate cardiovascular risk. (Funded by the Wellcome Trust and others; TIPS-3 ClinicalTrials.gov number, NCT01646437.).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Effects of the Polypill, as Compared with Placebo, on Systolic Blood Pressure, Heart Rate, and the Low-Density Lipoprotein (LDL) Cholesterol Level.
I bars indicate 95% confidence intervals (CIs).
Figure 2
Figure 2. Effects of the Polypill, as Compared with Placebo, on Clinical Outcomes.
Panel A shows the cumulative incidence of a first composite-primary-outcome event (death from cardiovascular causes, myocardial infarction, stroke, heart failure, resuscitated cardiac arrest, or arterial revascularization) for the comparison of the polypill with placebo. Panel B shows the cumulative incidence of first and recurrent events of the primary composite outcome. Insets show the same data on an enlarged y axis.
Figure 3
Figure 3. Effects of the Aspirin, as Compared with Placebo, on Clinical Outcomes.
Panel A shows the cumulative incidence of a first composite-primary-outcome event (death from cardiovascular causes, myocardial infarction, or stroke) for the comparison of aspirin with placebo. Panel B shows the cumulative incidence of the first event of cancer (component of the secondary outcome; a prespecified outcome). Insets show the same data on an enlarged y axis.
Figure 4
Figure 4. Effects of the Polypill plus Aspirin, as Compared with Double Placebo, on Clinical Outcomes.
Panel A shows the cumulative incidence of a first composite-primary-outcome event (death from cardiovascular causes, myocardial infarction, stroke, heart failure, resuscitated cardiac arrest, or arterial revascularization) for the comparison of combination therapy with a polypill plus aspirin with placebo. Panel B shows the cumulative incidence of first and recurrent events of the primary composite outcome. Insets show the same data on an enlarged y axis.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. GBD 2017 Causes of Death Collaborators. Global, regional, and national agesex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88. - PMC - PubMed
    1. Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395:785–94. - PubMed
    1. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1923–94. - PMC - PubMed
    1. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middleincome, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395:795–808. - PMC - PubMed
    1. The Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13. - PubMed

Publication types

MeSH terms

Associated data